SCHEMBL358766

SCHEMBL358766

O=C1c2ccccc2S(=O)(=O)N1Br

nearest known ligand 0.60

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 14/20 0.60
CA2 P00918 6/20 0.60
ELANE P08246 2/20 0.56
CA12 O43570 15/20 0.55
CYP2D6 P10635 1/20 0.49
TSHR P16473 1/20 0.49
LMNA P02545 1/20 0.49
CA1 P00915 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29413000 1.00 CA9 (0.60) CA9CA2ELANECA12CYP2D6
Pyridine SCHEMBL30619408 0.87 CA9 (0.47) CA9CA2ELANECA12
SCHEMBL29151571 0.78 ELANE (0.78) CA9CA2ELANECA12CYP2D6
SCHEMBL29386930 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6
SCHEMBL358829 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6
SCHEMBL29165711 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6
SCHEMBL476080 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6
SCHEMBL1779607 0.75 ELANE (0.61) CA9CA2ELANECA12CYP2D6
SCHEMBL29853810 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6
Saccharin Calcium SCHEMBL29394622 0.75 CA9 (0.60) CA9CA2ELANECA12CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025131772-A1 HARDENER SYSTEM FOR RADICALLY HARDENING REACTIVE RESINS USED IN CHEMICAL FASTENING HILTI AKTIENGESELLSCHAFT (LI) 2025-06-26 WO claimed
EP-4574853-A1 HARDENER SYSTEM FOR RADICALLY HARDENING REACTIVE RESINS USED IN CHEMICAL FASTENING Hilti Aktiengesellschaft (LI) 2025-06-25 EP claimed
US-20250011297-A1 PROCESS AND INTERMEDIATES FOR PREPARATION OF ISOFETAMID ADAMA MAKHTESHIM LTD. (IL) 2025-01-09 US claimed
CN-112119071-B Process for preparing anthranilamides PI工业有限公司 2024-08-02 CN claimed
US-20240174601-A1 COMPOSITION COMPRISING HETEROCYCLIC COMPOUND AND 4,4'-METHYLENE DIPHENYL DIISOCYANATE BASF SE (DE) 2024-05-30 US claimed
CN-117500778-A 2-substituted bicyclo [1.1.1] pentanes 普林斯顿大学保管委员会 2024-02-02 CN claimed
EP-4308542-A1 COMPOSITION COMPRISING HETEROCYCLIC COMPOUND AND 4,4'-METHYLENE DIPHENYL DIISOCYANATE BASF SE (DE) 2024-01-24 EP claimed
CN-117098751-A Composition comprising a heterocyclic compound and 4,4' -methylenediphenyl diisocyanate 巴斯夫欧洲公司 2023-11-21 CN claimed
EP-4267591-A2 ORGANOMETALLIC COMPOUNDS Umicore AG & Co. KG (DE) 2023-11-01 EP claimed
CN-112469687-B New method for preparing o-carboxamido benzamide compound PI工业有限公司 2023-10-13 CN claimed
US-20210206884-A1 PROCESSES FOR THE PREPARATION OF SUGAMMADEX MERCK SHARP & DOHME CORP. (US) 2021-07-08 US claimed
CN-112469687-A Novel method for preparing o-formamido benzamide compound PI工业有限公司 2021-03-09 CN claimed
CN-112449642-A Process for preparing sugammadex 默沙东公司 2021-03-05 CN claimed
CN-112119071-A Novel method for preparing o-formamido-benzamide compound PI工业有限公司 2020-12-22 CN claimed
WO-2020240375-A1 IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES DR. REDDY’S LABORATORIES LIMITED (IN) 2020-12-03 WO claimed
WO-2020212991-A1 PREPARATION OF SUBSTITUTED PYRAZOLES AND THEIR USE AS ANTHRANILAMIDES PRECURSORS ADAMA MAKHTESHIM LTD. (IL) 2020-10-22 WO claimed
WO-2019159191-A1 AN IMPROVED PROCESS FOR PREPARATION OF SUGAMMADEX SODIUM EXTROVIS AG EXTROVIS PRIVATE LIMITED (IN) 2019-08-22 WO claimed
US-20100234603-A1 Process for Making Substituted Aryl Sulfone Intermediates LINGHU XIN 2010-09-16 US claimed
US-4032348-A METHOD FOR FORMING PHASE HOLOGRAMS FUJI PHOTO FILM CO., LTD. (JA) 1977-06-28 US claimed
US-3948659-A BLEACHING FUJI PHOTO FILM CO., LTD. (JA) 1976-04-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174601-A1 COMPOSITION COMPRISING HETEROCYCLIC COMPOUND AND 4,4'-METHYLENE DIPHENYL DIISOCYANATE DBI, CCNI, MT-ND4 CA9 2142/4885CA2 3327/4885ELANE 2083/4885
US-20250011297-A1 PROCESS AND INTERMEDIATES FOR PREPARATION OF ISOFETAMID IDH2, FH, SDHA CA9 1027/4885CA2 1930/4885ELANE 4577/4885
US-20100234603-A1 Process for Making Substituted Aryl Sulfone Intermediates SULT1A1, SULT1E1, STS CA9 1389/4885CA2 3907/4885ELANE 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.